Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 April 2025 | Story Martinette Brits | Photo Kaleidoscope Studios
Jeremiah Hlahla
Jeremiah Hlahla, 27, proudly graduates with a PhD in Botany.

At just 27 years old, Dr Jeremiah Hlahla has achieved a remarkable milestone: earning his PhD in Botany, conferred on Thursday 10 April. His journey is one of perseverance, academic curiosity, and the determination to rise above significant personal and financial challenges.  

 

Resilience rooted in early hardship 

Growing up in Nkomazi, Mpumalanga, Dr Hlahla’s early life was marked by profound loss. His mother passed away when he was still young, and in Grade 11, he lost his father. Left without the support of his immediate family, he was placed in an orphanage alongside his sister. Despite these immense challenges, Dr Hlahla remained focused on his education.  

“From Grade 10, I stayed behind at school to do my homework and study,” he recalls. “By Grade 12, I asked the pastor if I could use the church office to study. He allowed me, and throughout matric, I would go straight from school to the church office.” 

 

A passion for science and a decisive pivot 

Dr Hlahla’s fascination with science began in Grade 4 when he first encountered the topic of Matter and Materials. “It was a fascinating subject for me,” he says. By Grade 9, he had decided to become a scientist, though he was still unsure of the specific field. 

After matric, he negotiated with an Anglo-American bursary manager to study biology instead of electrical engineering. “I later applied for biochemistry and botany at the University of Johannesburg because I enjoyed biology - but over the years, I found plant science especially interesting.” 

The pivotal moment in his life came when he was awarded an Anglo-American scholarship. “That was a huge turning point in my life,” he says. “After matric, I didn’t know what I would do next. But after one psychometric exam and two rounds of interviews, I received the scholarship, and my life improved.” 

With renewed motivation, he continued his studies and pursued a Master's degree, despite having no financial resources at the time. “When I arrived at the University of the Free State (UFS), I had just left Pretoria with my bags and no money,” he recalls. His supervisor, Dr Makoena Moloi, recommended him for a National Research Foundation (NRF) grant to cover his expenses. He was later awarded a bursary from Carl Zeiss. 

“Dr Moloi wanted a hardworking person,” Dr Hlahla says. “She also helped me improve my academic writing.”

 

Perseverance through a pandemic 

The COVID-19 pandemic brought unexpected setbacks, derailing his MSc research. “After the lockdown, I returned to find my plants had died. I had to start from scratch,” he says. Despite this, he completed his experiments by August 2021 and submitted his MSc with distinction. 

“It is incredibly rewarding to see years of hard work culminate in a PhD,” he reflects. 

 

Looking ahead: Researching for a food-secure future 

Now a postdoctoral researcher in plant breeding, Dr Hlahla is working on developing drought-tolerant edamame cultivars – research inspired by his PhD work. 

 “What excites me the most is breeding drought-tolerant edamame cultivars based on my previous research,” he says. “I am also thrilled to be working with Prof Maryke Labuschagne and Prof Rouxlene van der Merwe.” 

Dr Hlahla’s journey has given him insight into what it takes to succeed against the odds. His message to students navigating hardship is clear: 

“Stay focused on your goals. How you respond to what happens to you will determine your future. Someone is always willing to help - so find support and use it. Hard work, willingness, and determination will take you far.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept